Compare Dyne Therapeutics Inc. Common Stock (DYN) vs Jumia Technologies AG - ADR (JMIA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dyne Therapeutics Inc. Common Stock vs Jumia Technologies AG - ADR — how do they compare? Dyne Therapeutics Inc. Common Stock trades at $15.06 (market cap $2.86B), while Jumia Technologies AG - ADR trades at $5.74 (market cap $789.73M). The key difference: Dyne Therapeutics Inc. Common Stock is far larger — about 3.6× Jumia Technologies AG - ADR's market cap, and Dyne Therapeutics Inc. Common Stock is more actively traded (3,341,579 versus 1,367,204). Which is the better fit depends on your goals — on Pluang, investors hold Dyne Therapeutics Inc. Common Stock for 0 Days and Jumia Technologies AG - ADR for 29 Days on average.
| DYN | JMIA | |
|---|---|---|
Market Cap | $2.86B | $789.73M |
Volume | 3,341,579 | 1,367,204 |
Sector | Health | Consumer Cyclical |
52-Week High | $26.78 | $14.60 |
52-Week Low | $14.60 | $5.69 |
Typical Hold Time | 0 Days | 29 Days |
Enterprise Value | $2.18B | $755.37M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dyne Therapeutics (DYN) trades at $15.30, down 4.14% on the day, reflecting recent volatility amid mixed clinical trial news. The stock is in a neutral technical position with immediate support at $15 and resistance at $16. Fundamentally, the company is a clinical-stage biotech with no revenue, reporting a net loss of $446.21M in 2025, but maintains strong analyst support with an 85.7% buy rating and a $35.20 consensus price target. Recent news highlights progress in Phase 1/2 trials for neuromuscular diseases and a $375M public offering in July 2026 to fund development.
The investment case hinges on clinical success, offering significant upside to the price target, but carries high risk due to pre-revenue status, dependence on trial outcomes, and negative cash flow from operations. Investor sentiment is cautiously optimistic, buoyed by analyst confidence, though volatility from sector-specific news remains a near-term challenge.
JMIA stock trades at $5.79, down 5.24% on the day, amid a bearish technical outlook with all moving averages signaling sell. Fundamentally, the company reported a net loss of $61.55 million in 2025, though revenue grew to $188.93 million and the net loss margin improved to -32.58%. Recent news highlights a $50 million capital raise and progress toward EBITDA breakeven by year-end 2026, per company reports from August 2026.
The outlook is mixed: analyst consensus is bullish with a $12 price target, but high execution risks persist given persistent losses and negative ROE. Investors face volatility from operational cash burn and competitive pressures in African e-commerce, though cost controls and growth initiatives offer potential upside if profitability targets are met.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Dyne Therapeutics Inc. Common Stock
Dyne Therapeutics, Inc. is a clinical-stage biotechnology company developing therapeutics for genetically driven neuromuscular diseases, including Duchenne muscular dystrophy and myotonic dystrophy type 1, with additional preclinical programs for facioscapulohumeral muscular dystrophy and Pompe disease.
Read more on DYN →About Jumia Technologies AG - ADR
Jumia Technologies AG is the pan-African e-commerce platform. The company's platform consists of a marketplace, which connects sellers with consumers. Its logistics service enables the shipment and delivery of packages from sellers to consumers, and the company's payment service facilitates transactions among participants active on its platform in selected markets. Jumia generates revenue from Sales of goods, Commissions, Fulfillment, Value-added services, and Marketing & Advertising. Its geographical segments are West Africa, North Africa, East & South Africa, Europe, and United Arab Emirates. The firm generates most of its revenue from the West Africa segment.
Read more on JMIA →
